Fate Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 2.17 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 260.01M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum...